First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants with B-cell Malignancies
Primary:
To characterize the safety and confirm tolerability of ABBV-101
Secondary:
To evaluate the pharmacokinetics (PK) following oral dose administration of ABBV-101
To evaluate the preliminary efficacy of ABBV-101 in specified subsets of participants with R/R B-cell NHL as defined by the disease-specific response criteria
- Rutgers Cancer Institute of New Jersey
- Principal Investigator
- Joanna Rhodes MD
- Principal Investigator
Inclusion Criteria
- For Dose Escalation (Part 1) only: Participants with documented diagnosis for one of
the following 3L+ B-cell malignancies, from one of the following WHO-defined
histologies (Swerdlow et al 2016):
- Chronic lymphocytic leukemia (CLL)
- Small lymphocytic lymphoma (SLL)
- Chimeric antigen receptor T-cells (CAR-T)/hematopoietic cell transplant (HCT)
relapsed/refractory (R/R) or ineligible diffuse large b-cell lymphoma (DLBCL)
from the following histologies: DLBCL not otherwise specified (NOS) (germinal
center B cell [GCB] and non-GCB DLBCL), T-cell/histiocyte-rich large B-cell
lymphoma, primary mediastinal (thymic) large B-cell lymphoma, intravascular large
B-cell lymphoma, anaplastic lymphoma kinase positive (ALK+) large B-cell
lymphoma, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6
rearrangements, and high-grade B-cell lymphoma NOS.
- Mantle cell lymphoma (MCL)
- Follicular lymphoma [FL] (grades 1-3b)
- Marginal zone lymphoma [MZL] (splenic, extranodal, and nodal)
- Waldenström macroglobulinemia (WM)
- Transformed indolent non-Hodgkin's lymphoma (iNHL)
- For Dose Expansion (Part 2) only: Participants with documented diagnosis of CLL who
are 3L+ including those with Bruton's tyrosine kinase (BTK) mutations or CAR-T/HCT R/R
or ineligible non-GCB DLBCL who are 3L+ with histology based on criteria established
by the World Health Organization (WHO).
- Has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1, or
2.
- Participant has a life expectancy >= 12 weeks.
- Prior Bruton's tyrosine kinase inhibitor (BTKi) is allowed.
- Adequate hematologic, renal, and hepatic function per the protocol.
- Participants with prior central nervous system (CNS) disease that have been
effectively treated may be eligible.
Exclusion Criteria
- Previously treated with a Bruton's tyrosine kinase (BTK) degrader.
- Known active CNS disease, or primary CNS lymphoma.
- Uncontrolled active systemic infection, or active cytomegalovirus infection, known
history of human immunodeficiency virus (HIV), active hepatitis B or C infection.
Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site ClinicalTrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.
For further information about clinical trials, please contact us at 732-235-7356.